Enzene appoints new site lead of biologics manufacturing

He will lead the final stages of work to commission the 54,000-square-foot facility and then lead ongoing operations at the site

Roche’s fenebrutinib demonstrated near-complete suppression of disease activity and disability progression

New Phase II data show vast majority of patients experiencing no relapses or disability progression

Siegfried opens quality control lab in Minden

The new facility further improves the operational efficiency and readies the site for the completion of the new large-scale production plant

Lupin launches Mirabegron ER tablets in US

Mirabegron Extended-Release Tablets, 50 mg is a generic equivalent of Myrbetriq® Extended-Release Tablets, 50 mg of Astellas Pharma Global Development

Lupin launches Doxorubicin Hydrochloride Liposome Injection in US

ForDoz Pharma Corporation, USA (ForDoz) received an approval for its ANDA from the USFDA

Roche’s PiaSky approved in the EU for treatment of people with PNH

PiaSky advances C5 inhibition through innovative recycling technology, which enables its monthly SC administration

Finerenone showed statistically significant improvement in cardiovascular outcomes in adults with common form of heart failure

Finerenone is the first mineralocorticoid receptor (MR) antagonist to demonstrate definitive cardiovascular benefits in a Phase III study in patients with heart failure (HF) with a left ventricular ejection fraction (LVEF) of ?40%

Merck announces first patient dosed in Phase III study of Oral Cladribine in gMG

MyClad is a global Phase III study evaluating the efficacy and safety of cladribine capsules for the treatment of generalized Myasthenia Gravis (gMG)

DKSH partners with Hasten Biopharmaceutical’s growth in Thailand

Indian doctor participates in Jordan’s first robotic radical hysterectomies